Table 1.

Comparison of Normal Hematocrit Cardiac Trial participants from the hematocrit normalized group that were included versus excluded in the analysis

VariableIncluded (n = 321)Excluded (n = 297)
Age (yr)65 ± 1265 ± 12
    >65 yr (%)5454
Gender, female (%)4852
Diabetes mellitus (%)5454
Race/ethnicity (%)
    white4644
    black4042
    other1414
Time on dialysis (yr)3.2 ± 3.63.4 ± 4.0
Vascular access (%)
    graft6667
    natural fistula2319
    other/not specified1214
Current hypertension (%)7072
Peripheral vascular disease (%)4037
Cardiac-related hospitalizations (%)7374
Hematocrit (%)30.4 ± 2.930.7 ± 3.1
Epoetin alfa dose (U/kg per wk)a,b164 ± 103137 ± 127
Albumin (g/L)37.4 ± 3.737.3 ± 3.5
Creatinine (μmol/L)849 ± 274875 ± 292
Transferrin saturation (%)26.2 ± 13.027.6 ± 12.8
White blood cell count (×109/L)7.0 ± 2.27.1 ± 2.3
Lymphocytes (% of white blood cell count)23.2 ± 9.622.6 ± 9.0
Mortality (%)2522
  • Categorical data are percentages and continuous measures are mean ± standard deviation (SD).

  • a P = 0.004.

  • b Includes 37 participants with a dose of zero for the week before randomization (5 of whom were excluded based on multiple criteria).